Species: | Rabbit |
Applications: | WB IF ICC |
Immunogen Range: | A synthetic peptide |
Clonality: | Polyclonal Antibody |
Isotype: | IgG |
GENE ID: | 8744 |
Swiss Prot: | P41273 |
Synonyms: | Tumor necrosis factor ligand superfamily member 9, 4-1BB ligand, 4-1BBL, TNFSF9 |
Purification: | Affinity purification |
Storage: | Store at -20°C or -80°C in PBS with 0.02% sodium azide and 50% glycerol. Avoid freeze/thaw cycles. |
Background: | Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also referred to as Apo2 ligand, first identified based on its sequence homology to TNF and Fas/Apo ligand is a member of the TNF family of cytokines and either exists as a type II membrane or soluble protein (1,2). TRAIL induces apoptosis in a variety of transformed cell lines and plays a role in anti-tumor and anti-viral immune surveillance (3). TRAIL signals via binding with death receptors DR4 (TRAIL-R1) (4) and DR5 (TRAIL-R2) (5-8) which can trigger apoptosis as well as NF-κB activation (7,9). Death domains on these receptors leads to the recruitment of a death-induced signaling complex (DISC) leading to caspase-8 and subsequent caspase-3 activation. In addition, TRAIL binds with decoy receptors DcR1 (TRAIL-R3) (10-13) and DcR2 (TRAIL-R4, TRUNDD) (14-15) which lack the functional cytoplasmic death domain antagonizing TRAIL-induced apoptosis. Osteoprotegerin (OPG) has also been identified as receptor capable of inhibiting TRAIL-induced apoptosis (16). The selectivity of soluble TRAIL at triggering apoptosis in transformed cells as compared to normal cells has led to its investigation as a potential cancer therapeutic (17-18). |
Caculated MW: | 23 kDa |
Observed MW: | Refer to Figures |
Applications: |
WB 1:500-1:1000 IF 1:100-1:500 ICC 1:100-1:500 |
Reacitivity: | Human |